Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

• Adam S. Kittai,
• Scott Best,
• Bria Thurlow,
• Vi Lam,
• Taylor Hashiguchi,
• Shaun Goodyear,
• Daniel O. Persky,
• Craig Okada,
• Byung Park,
• Stephen E. Spurgeon,
• Alexey V. Danilov

Affiliations

Adam S. Kittai

Knight Cancer Institute, Oregon Health and Science University, Portland, OR

Scott Best

Knight Cancer Institute, Oregon Health and Science University, Portland, OR

Bria Thurlow

Knight Cancer Institute, Oregon Health and Science University, Portland, OR

Vi Lam

Knight Cancer Institute, Oregon Health and Science University, Portland, OR

Taylor Hashiguchi

Knight Cancer Institute, Oregon Health and Science University, Portland, OR

Shaun Goodyear

Knight Cancer Institute, Oregon Health and Science University, Portland, OR

Daniel O. Persky

University of Arizona Cancer Center, Tucson, AZ

Craig Okada

Knight Cancer Institute, Oregon Health and Science University, Portland, OR

Byung Park

Knight Cancer Institute, Oregon Health and Science University, Portland, OR

Stephen E. Spurgeon

Knight Cancer Institute, Oregon Health and Science University, Portland, OR

Alexey V. Danilov

Knight Cancer Institute, Oregon Health and Science University, Portland, OR; City of Hope Comprehensive Cancer Center, Duarte, CA